Male Hypogonadism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Male hypogonadism is a condition in which the body doesn’t produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, a decrease in muscle mass, and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles, and untreated sleep apnea. Treatment includes hormone replacement.

The Male Hypogonadism drugs in development market research report provide comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects.

Key Targets in the Male Hypogonadism Pipeline Products Market

The key targets in the Male Hypogonadism pipeline products market are Androgen Receptor, Estrogen Receptor, Follicle Stimulating Hormone Receptor, Voltage Dependent Anion Selective Channel Protein 1, Aromatase, Estrogen Receptor Beta, KiSS 1 Receptor, and Lutropin Choriogonadotropic Hormone Receptor.

Male Hypogonadism Pipeline Products Analysis Market by Targets

Male Hypogonadism Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Male Hypogonadism Pipeline Products Market

The key mechanisms of action in the Male Hypogonadism pipeline products market are Androgen Receptor Agonist, Estrogen Receptor Antagonist, Follicle Stimulating Hormone Receptor Agonist, Voltage Dependent Anion Selective Channel Protein 1 Blocker, Aromatase Inhibitor, Estrogen Receptor Beta Antagonist, KiSS 1 Receptor Agonist, and Lutropin Choriogonadotropic Hormone Receptor Agonist.

Male Hypogonadism Pipeline Products Market Analysis by Mechanism of Actions

Male Hypogonadism Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Male Hypogonadism Pipeline Products Market

The key routes of administration in the Male Hypogonadism pipeline products market are oral, nasal, transdermal, buccal, intramuscular, intravenous, and subcutaneous.

Male Hypogonadism Pipeline Products Market Analysis by Routes of Administration

Male Hypogonadism Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Male Hypogonadism Pipeline Products Market

The key molecule types in the Male Hypogonadism pipeline products market are small molecule, peptide, recombinant protein, and synthetic peptide.

Male Hypogonadism Pipeline Products Market Analysis by Molecule Type

Male Hypogonadism Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Male Hypogonadism Pipeline Products Market

Some of the major companies in the Male Hypogonadism pipeline products market are IASO BioMed Inc, Met P Pharma AG, AbbVie Inc, Beijing FuKangren Bio-pharm Tech Co Ltd, Chong Kun Dang Pharmaceutical Corp, Diurnal Group Plc, Endoceutics Inc, Function Promoting Therapies LLC, Lennham Pharmaceuticals Inc, and Lipocine Inc.

Male Hypogonadism Pipeline Products Market Analysis by Companies

Male Hypogonadism Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Androgen Receptor, Estrogen Receptor, Follicle Stimulating Hormone Receptor, Voltage Dependent Anion Selective Channel Protein 1, Aromatase, Estrogen Receptor Beta, KiSS 1 Receptor, and Lutropin Choriogonadotropic Hormone Receptor
Key mechanism of action Androgen Receptor Agonist, Estrogen Receptor Antagonist, Follicle Stimulating Hormone Receptor Agonist, Voltage Dependent Anion Selective Channel Protein 1 Blocker, Aromatase Inhibitor, Estrogen Receptor Beta Antagonist, KiSS 1 Receptor Agonist, and Lutropin Choriogonadotropic Hormone Receptor Agonist
Key routes of administration Oral, Nasal, Transdermal, Buccal, Intramuscular, Intravenous, and Subcutaneous
Key molecule type Small Molecule, Peptide, Recombinant Protein, and Synthetic Peptide
Major companies IASO BioMed Inc, Met P Pharma AG, AbbVie Inc, Beijing FuKangren Bio-pharm Tech Co Ltd, Chong Kun Dang Pharmaceutical Corp, Diurnal Group Plc, Endoceutics Inc, Function Promoting Therapies LLC, Lennham Pharmaceuticals Inc, and Lipocine Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
Beijing FuKangren Bio-pharm Tech Co Ltd
Chong Kun Dang Pharmaceutical Corp
Diurnal Group Plc
Endoceutics Inc
Function Promoting Therapies LLC
IASO BioMed Inc
Lennham Pharmaceuticals Inc
Lipocine Inc
M et P Pharma AG
Marius Pharmaceuticals LLC
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
MHB Labs
Solural Pharma ApS
TesoRx Pharma LLC
Transdermal Delivery Solutions Corp
Viramal Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Male Hypogonadism – Overview

Male Hypogonadism – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Male Hypogonadism – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Male Hypogonadism – Companies Involved in Therapeutics Development

AbbVie Inc

Beijing FuKangren Bio-pharm Tech Co Ltd

Chong Kun Dang Pharmaceutical Corp

Diurnal Group Plc

Endoceutics Inc

Function Promoting Therapies LLC

IASO BioMed Inc

Lennham Pharmaceuticals Inc

Lipocine Inc

M et P Pharma AG

Marius Pharmaceuticals LLC

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

MHB Labs

Solural Pharma ApS

TesoRx Pharma LLC

Transdermal Delivery Solutions Corp

Viramal Ltd

Male Hypogonadism – Drug Profiles

chorionic gonadotropin ER – Drug Profile

Product Description

Mechanism Of Action

corifollitropin alfa – Drug Profile

Product Description

Mechanism Of Action

History of Events

enclomiphene citrate – Drug Profile

Product Description

Mechanism Of Action

History of Events

IAS-167A – Drug Profile

Product Description

Mechanism Of Action

History of Events

Kisspeptin-10 – Drug Profile

Product Description

Mechanism Of Action

History of Events

leflutrozole – Drug Profile

Product Description

Mechanism Of Action

History of Events

Libidua – Drug Profile

Product Description

Mechanism Of Action

LPCN-1111 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Peptides to Block VDAC1 for Hypogonadism – Drug Profile

Product Description

Mechanism Of Action

Rifene – Drug Profile

Product Description

Mechanism Of Action

testosterone – Drug Profile

Product Description

Mechanism Of Action

History of Events

testosterone – Drug Profile

Product Description

Mechanism Of Action

History of Events

testosterone – Drug Profile

Product Description

Mechanism Of Action

History of Events

testosterone – Drug Profile

Product Description

Mechanism Of Action

History of Events

testosterone – Drug Profile

Product Description

Mechanism Of Action

testosterone – Drug Profile

Product Description

Mechanism Of Action

testosterone – Drug Profile

Product Description

Mechanism Of Action

History of Events

testosterone – Drug Profile

Product Description

Mechanism Of Action

testosterone propionate – Drug Profile

Product Description

Mechanism Of Action

testosterone undecanoate – Drug Profile

Product Description

Mechanism Of Action

History of Events

testosterone undecanoate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Male Hypogonadism – Dormant Projects

Male Hypogonadism – Discontinued Products

Male Hypogonadism – Product Development Milestones

Featured News & Press Releases

Mar 02, 2022: Regulatory update on oral native testosterone

Jan 27, 2022: Lipocine announces peer-reviewed publication of phase 3 study results for TLANDO

Oct 11, 2021: Phase 1 data for DITEST published in European Journal of Endocrinology

Oct 11, 2021: Phase 1 data for DITEST published in European Journal of Endocrinology

Sep 28, 2021: Lipocine announces FDA affirmation of class 1 NDA resubmission for TLANDO

Jun 29, 2021: Acerus announces new PBM contract, significantly expanding NATESTO insurance coverage in the United States

Jun 11, 2021: Marius announces ambulatory blood pressure results published in the Journal of Clinical Hypertension with their new testosterone medication KYZATREX

Mar 30, 2021: Acerus announces expansion of NATESTO distribution worldwide

Mar 11, 2021: Marius Pharmaceuticals receives PDUFA date for KYZATREX NDA for treatment of hypogonadism

Jan 28, 2021: Marius Pharmaceuticals announces Co-CEOs Himanshu H. Shah and Shalin Shah to drive growth ahead of anticipated FDA action of its lead asset, KYZATREX

Jan 28, 2021: Marius Pharmaceuticals announces Co-CEOs Himanshu H. Shah and Shalin Shah to drive growth ahead of anticipated FDA action of its lead asset, KYZATREX

Jan 05, 2021: Marius Pharmaceuticals submits New Drug Application to U.S. FDA for next-generation oral testosterone replacement therapy in male patients with hypogonadism

Jan 05, 2021: Marius Pharmaceuticals submits New Drug Application to U.S. FDA for next-generation oral testosterone replacement therapy in male patients with hypogonadism

Jan 05, 2021: Marius Pharmaceuticals submits New Drug Application to U.S. FDA for next-generation oral testosterone replacement therapy in male patients with hypogonadism

Jul 30, 2020: Diurnal Group announces positive DITEST regulatory meeting with US FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Male Hypogonadism, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Male Hypogonadism – Pipeline by AbbVie Inc, 2022

Male Hypogonadism – Pipeline by Beijing FuKangren Bio-pharm Tech Co Ltd, 2022

Male Hypogonadism – Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022

Male Hypogonadism – Pipeline by Diurnal Group Plc, 2022

Male Hypogonadism – Pipeline by Endoceutics Inc, 2022

Male Hypogonadism – Pipeline by Function Promoting Therapies LLC, 2022

Male Hypogonadism – Pipeline by IASO BioMed Inc, 2022

Male Hypogonadism – Pipeline by Lennham Pharmaceuticals Inc, 2022

Male Hypogonadism – Pipeline by Lipocine Inc, 2022

Male Hypogonadism – Pipeline by M et P Pharma AG, 2022

Male Hypogonadism – Pipeline by Marius Pharmaceuticals LLC, 2022

Male Hypogonadism – Pipeline by Medlab Clinical Ltd, 2022

Male Hypogonadism – Pipeline by Merck & Co Inc, 2022

Male Hypogonadism – Pipeline by Mereo Biopharma Group Plc, 2022

Male Hypogonadism – Pipeline by MHB Labs, 2022

Male Hypogonadism – Pipeline by Solural Pharma ApS, 2022

Male Hypogonadism – Pipeline by TesoRx Pharma LLC, 2022

Male Hypogonadism – Pipeline by Transdermal Delivery Solutions Corp, 2022

Male Hypogonadism – Pipeline by Viramal Ltd, 2022

Male Hypogonadism – Dormant Projects, 2022

Male Hypogonadism – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Male Hypogonadism, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Male Hypogonadism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Male Hypogonadism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Male Hypogonadism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.